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The association between cancer and venous thromboembolism (VTE) is well established. Saddle pulmonary embolism is not
uncommon in hospitalized cancer patients and confers a higher mortality. We report a case of saddle pulmonary embolism in
a cancer patient with thrombocytopenia, discuss the bleeding risks, complexity of managing such patients and review current
guidelines.
1.Introduction
Pulmonary embolism (PE) is common in hospitalized pa-
tients. Overall mortality for major pulmonary embolism is
22% and as high as 65% in those who require cardiopul-
monary resuscitation [1]. Saddle pulmonary embolism in
cancer patients carries a very poor prognosis, with mortality
of >80% at one year [2]. A number of patients with cancer
and pulmonary embolism have concomitant thrombocy-
topenia, posing a great therapeutic challenge.
Wereportacaseofsaddlepulmonaryembolisminacan-
cer patient with thrombocytopenia and discuss the bleeding
risks, complexity of managing such patients and review cur-
rent guidelines.
2.CaseReport
A 73-year-old female with history of hepatocellular carci-
noma due to long-standing hepatitis C, presented to the
emergency center with a sudden syncopal episode at home.
Her past medical history was signiﬁcant for portal hyper-
tension, and variceal bleeding requiring blood transfusions.
She was receiving sorafenib, which required dose reduction
due to thrombocytopenia. Her platelets ﬂuctuated between
46,000–113×109 during the treatment.
On examination she was stable with a blood pressure of
128/72mmHg; heart rate of 80 beats per minute; respiratory
rate of 22/minute; temperature 36.7◦C; and O2 saturation of
96% on 2-3 liters oxygen via nasal cannula. Heart sounds
were normal with no signs of heart failure.2 Cardiology Research and Practice
Figure 1:CTscanshowingasaddlepulmonaryembolus,extending
into the right and left pulmonary arteries.
Relevant investigations included a 12 lead electrocar-
diogram (ECG), which showed sinus rhythm with left axis
deviation, and no evidence of ischemia.
Serum troponin was marginally elevated at 0.12ng/mL
(Normal values: 0.00–0.03ng/mL). Computerized (CT) scan
ofthelungsshowedsaddlePEwithextensionintothelobular
braches (Figure 1). Chest X-ray was normal and venous
Doppler study of the legs showed a partially attached right
femoral thrombus. Platelet count was 60×109/L (Normal
values: >150,000×109/L) and D-dimer was >20.00mcg/mL
(Normal values: 0.00–0.4mcg/mL). Hemoglobin, interna-
tional normalized ratio (INR), activated partial thrombo-
plastin time (aPTT), renal and liver function tests were
within normal limits. Echocardiogram showed normal left
and right ventricular (RV) systolic function with no peri-
cardial eﬀusion. Right ventricular systolic pressure was
29mmHg.
She was treated with LMWH (Enoxaparin in a dose of
1mg/kg subcutaneously twice daily) and inferior vena cava
(IVC) ﬁlter was placed to prevent migration of the lower
extremity thrombus. In view of her thrombocytopenia, he-
modynamic stability and no evidence of RV dysfunction, she
was not given thrombolytics. The patient’s hemoglobin and
platelets remained stable throughout the hospitalization and
she was discharged home on LMWH.
3. Discussion
Venous thromboembolism (VTE) is common in cancer pa-
tients; with signiﬁcant in hospital mortality [1, 3]. In a large
retrospective cohort study of hospitalized cancer patients,
overall incidence of VTE was 4.1% [4]. Cancer patients with
VTE have higher in-hospital mortality compared to those
who did not have VTE (16.3% versus 6.3%; P<. 001) [4].
In patients with PE, comorbidities like older age (>70 years),
congestive heart failure, RV dysfunction and cancer increase
the likelihood of mortality by at least 2-3-fold [3].
Cancer induces a prothrombotic state [5, 6]. Malignant
neoplasm alone is associated with a 4-fold increased risk of
VTE without chemotherapy, and cytotoxic immunosuppres-
sive therapy increases the risk to more than 6-fold [7]. The
most common chemotherapy agents associated with VTE
are: thalidomide, lenalidomide with or without dexametha-
sone, L-asparginase, bevacizumab, tamoxifen, estramustine,
capecitabine, erlotinib, sunitinib, vinorelbine, trastuzumab,
paclitaxel-albumin-bound, letrozole, and bortezomib [8]. In
addition to chemotherapy agents, central venous catheters
(CVC) also act as predisposing factors. The incidence of
venographicCVC-relatedDVTincancerpatientsvariesfrom
27% to 66% [9]. Risk of VTE also increases signiﬁcantly in
patients undergoing major surgical procedures for cancer
[10].
Saddle pulmonary embolism in cancer patients carries a
very poor prognosis, with mortality of >80% at one year [2].
The treatment of saddle pulmonary embolism, particularly
in the setting of concomitant thrombocytopenia, remains
unclear and creates a great therapeutic challenge. The
issue of treating thrombotic disease in cancer patients with
thrombocytopenia secondary to myelosuppressive therapy
has not been studied in large randomized clinical trials and
therapy in these cases should be individualized based on risk
beneﬁt ratio.
3.1. Examining Guidelines for Treatment of PE. Treatment
of saddle PE includes anticoagulants, thrombolytics and
catheter based or surgical embolectomy [2]. In the absence
of any large scale data, treatment should be individualized
according to clinical status, evidence of RV dysfunction,
cancer staging and risk of bleeding. Anticoagulants (heparin
and warfarin) remain an integral part of all treatment plans.
3.2. Anticoagulants. National and international guidelines
recommend LMWH as the ﬁrst-line agent and Vitamin K
antagonist (VKA) warfarin as a second line agent for the
initial and long-term treatment of VTE in cancer patients
[11–15]( Table 1). These recommendations are based on 4
clinical trials of VTE in cancer patients, comparing LMWH
with warfarin from 3–6 months duration. Data beyond 6
months treatment with either LMWH or warfarin do not
exist.
In a study of 146 cancer patients with VTE, in which
enoxaparin 1.5mg/kg was compared to warfarin (INR goal
of 2-3), there were no signiﬁcant diﬀerences at 3 months
between the two treatment groups based on combined
outcomes of recurrent VTE or major bleeding episodes
(warfarin 21.1%; (95% conﬁdence interval (CI), 12.3%–
32.4%) versus enoxaparin 10.5%; (95% CI, 4.3%–20.3%);
(P = .09)). This study enrolled only 47% cancer patient with
DVT and PE without hemodynamic instability [16].
In another randomized trial of 676 cancer patients
with VTE in which dalteparin in a dose adjusted protocol
(200IU/Kgdailyfortheﬁrstmonthandthen150IU/Kgdaily
for the next 5 months) was compared to warfarin, there wasCardiology Research and Practice 3
Table 1: Summary of guidelines for treatment of VTE in cancer [11–15].
Condition ASCO NCCN AIOM/ESMO ACCP
Initial treatment (acute
phase)
-5 – 1 0d a y s=LMWH
preferred
- LMWH, UFH (IV),
FXa-I according to clinical
situation
- LMWH, UFH (IV)
F o rC r C ll e s st h a n
25–30mL/min, either
LMWH, UFH with antiXa
monitoring
-L M W Ho rV K Af o r
minimum of 90 days
Long-term treatment
(chronic phase)
- LMWH for 180 days
- If LMWH not available
then VKA
- indeﬁnite in active
disease
-L M W Hp r e f e r r e d
- Indeﬁnite in patients
with active and persistent
RF
- DVT for 3–6 months
- PE for 6–12 months
- LMWH for 90–180 days
- Long-term for patients
with active cancer
-L M W Ho rV K Af o ra s
long as cancer active
Thrombolytic for initial
treatment
Only in limb-threatening
thrombosis
Massive DVT or PE with
hemodynamic instability NA NA
IVCF
- Presence of CI
- Recurrent VTE despite
AC
- Presence of CI
- New PE that might be
life-threatening of PHTN
- Presence of CI
- Recurrent PE despite
treatment
- In patients with acute PE,
if anticoagulant is not
possible due to high-risk of
bleeding
- As soon as risk of bleeding
is minimal, AC should be
started
VTE:venousthromboembolism;ASCO:AmericanSocietyofClinicalOncology;NCCN:NationalComprehensiveCancerNetwork;AIOM:ItalianAssociation
of Medical Oncology; ESMO:European Society of Medical Oncology; ACCP:American College of Chest Physician; LMWH:low-molecular-weight-
heparin; UFH:unfractionated heparin; FXa-I:factor- Xa inhibitor; VKA:vitamin K antagonist; RF:risk factors; DVT:deep-vein thrombosis; PE:pulmonary
embolism; IVCF:inferior vena-caval ﬁlter; CI:contraindication; PHTN:pulmonary hypertension; AC:anticoagulation; IV:intravenous; NA: not addressed.
CrCl: creatinine clearance.
asigniﬁcant decreasein the cumulativerisk of recurrentVTE
in patients receiving dalteparin compared to warfarin (8.3%
versus 15.8%; hazard ratio, 0.48; P = .002). PE with or with-
out DVT comprised only 30% of total enrolled patients [17].
In another trial of 91 cancer patients with VTE, in
which 3 diﬀerent regimens were compared: (1) enoxaparin
1.0mg/Kg twice daily for 5 days followed by once daily
1.0mg/Kg for175 days;(2) enoxaparin 1.0mg/Kg twicedaily
for 5 days then enoxaparin 1.5mg/Kg once daily for 175
days; (3) enoxaparin 1.0mg/Kg twice daily with warfarin for
minimum of 5 days with an INR goal of 2-3; there were no
signiﬁcant diﬀerences between enoxaparin and warfarin in
safety proﬁle and recurrent VTE. In this study 45% of cancer
patient with VTE had PE [18].
In a recent study of 200 cancer patients with VTE, in
which tinzaparin in a dose of 175 International Factor Xa
Inhibitory Units/Kg was compared to warfarin for an INR
goal of 2-3, there was a signiﬁcant decrease in cumulative
risk of recurrent VTE at 10 months in patients assigned to
tinzaparin (P = .044) [19]. In this trial, only 21% of patient
had PE [19]. A recent meta-analysis showed superiority
of LMWH over VKA in lowering rates of recurrent VTE
in cancer patients [20]. Low-molecular-weight heparins
(LMWHs) have become anticoagulants of choice due to
their predictable pharmacokinetic and pharmacodynamic
proﬁles. These agents are not therapeutically interchangeable
due to their diﬀerent molecular weight, half-life, and antiXa
to IIa ratio [21]. LMWHs are considered intermediate acting
anticoagulants with predictable kinetics. Speciﬁc pharma-
cokinetics of diﬀerent anticoagulants, platelet monitoring,
and recommendation for reversal in cases of bleeding are
reviewed in Table 2. Monitoring of antiXa is recommended
in obese patients, underweight patients, and patients with
renal insuﬃciency, dueto accumulation of LMWHs[22–27].
Warfarin is considered an alternative agent to LMWH.
Due to major drug interactions between warfarin and
chemotherapy, nutritional deﬁciency, and use of nonchem-
otherapy agents in cancer patients, frequent dose monitoring
and modiﬁcations for warfarin is needed.
The diﬃculty in maintaining the narrow therapeutic
index of warfarin also was shown in a major cancer trial
where a therapeutic range INR (2-3) was achieved in only
46% of the patients [17]. Risk of VTE recurrence increases
with subtherapeutic INR [30].
Direct factor-Xa inhibitor, fondaparinux, can also be
considered for the initial (acute phase) treatment of PE.
Fondaparinux was studied in a randomized clinical trial that
showednoninferioritytounfractionatedheparinintheacute
treatment of PE; however, only 20% of patients enrolled
in each arm had cancer. The incidence of VTE recurrence
was 3.8% in the fondaparinux group and 5.0% in the
unfractionated-heparin group, for an absolute diﬀerence in
favor of fondaparinux of 1.2% (95% conﬁdence interval,
−3.0 to 0.5). The reported incidence of major bleeding was
2% in the fondaparinux group and 2.4% in the unfraction-
ated heparin [33] .D u et ol a c ko fe x t e n d e dt r e a t m e n tt r i a l s ,
the role of fondaparinux for long-term treatment of VTE in
cancer patients in unknown [13–15, 28].
Recently ﬁxed-dose subcutaneous weight-adjusted un-
fractionated heparin (UFH) has also been recommended
for the acute treatment of VTE [15] .T h es t r e n g t ho ft h i s
recommendation is weak and is based only on 2 studies,4 Cardiology Research and Practice
Table 2: Pharmacokinetics of diﬀerent anticoagulants [22–29].
Anticoagulant Molecular
weight
T1/2
(h) Elimination route Antidote Platelet monitoring AntiXa monitoring
Enoxaparin
(lovenox)
3,500–
5,500 4.5–7 Renal
- Thrombocytopenia of any
degree should be
monitored closely
- Discontinue for platelet
count falls below
100,000/mm3
-1m g / k g
Q12=0.6–1.1IU/mL
-1 . 5m g / k g
daily=1.0–1.5 IU/mL
Dalteparin
(fragmin)
5,600–
6,400 3–5 Renal
Protamine sulfate 1mg per
100U of heparin or less
than 100mg over 2 hours
to lower risk of reaction.
Protamine partially reverses
the eﬀect of LMWH
- For platelet counts
between 50,000 and
100,000/mm3, reduce dose
of dalteparin by 2,500IU
until the platelet count
recovers to ≥100,000/mm3
- Discontinue for platelet
counts <50,000/mm3
- 100IU/kg
Q12=0.4–1.1IU/mL
- 200IU/kg
daily=1.0-2.0IU/mL
Tinzaparin
(innohep)
5,600–
7,500 3-4 Renal
- Thrombocytopenia of any
degree should be
monitored
- Discontinue for platelet
count below 100,000/mm3
175IU/kg=0.85–
1.0IU/mL
Unfractionated
heparin
5,000–
30,000 1-2 Renal/endothelial
Protamine sulfate 1mg per
100U of heparin or less
than 100mg over 2 hours
to lower risk of reaction.
- Thrombocytopenia of any
degree should be
monitored
- Discontinue for platelet
count below 100,000/mm3
or if recurrent thrombosis
develops (sign and
symptoms of HIT)
aPTT monitoring
Fondaparinux
(arixtra) <2,500 17–
21 Renal Recombinant factor VIIa
90mcg/kg
- Thrombocytopenia of any
degree should be
monitored
- Discontinue for platelet
count falls below
100,000/mm3
-2 . 5m g=peak at steady
state 0.39–0.5mg/L;
trough at steady state
0.14–0.19mg/L
- 5mg, 7.5mg,
10mg=peak at steady
state 1.20–1.26mg/L;
trough at steady state
0.46–0.62mg/L
IV: intravenous; SC: subcutaneous; U: unit; UFH: unfractionated heparin; LMWH: low-molecular-weight heparin; T1/2: half-life elimination; HIT: heparin-
induced thrombocytopenia; aPTT: activated partial thromboplastin time.
each including only 22% patients with cancer with less
than 20% patients with PE. Patients with hemodynamic
compromise were excluded from these trials; therefore, PE
patients with cardiovascular compromise should not receive
UFH subcutaneously [15].
Recommended treatment duration of VTE in cancer
patients is 6–12 months and indeﬁnite in cases of metastatic
or active cancer [11–15].
3.3. Thrombolytics. In the absence of contraindications,
systemicthrombolyticsshouldbeconsideredinpatientswith
massive PE and hemodynamic instability [11, 15]. The
recommended dose of r-tPA is 100mg intravenously over 2
hours via peripheral vein [15].
However, cancer patients have been excluded from
thrombolytic trials; hence evidence-based guidelines for the
use of thrombolytics in this subset of population is lacking.
Except for a case report where streptokinase was used
for the treatment of PE associated with heparin-induced
thrombocytopenia [35], no other data exists on the use of
thrombolytics in patients with PE and thrombocytopenia.
Clinicaljudgmentshouldbeusedandtherapyindividualized
in each case.
3.4.Thrombectomy. Catheterandsurgicalthrombectomyare
an option in selected patients. In a pregnant patient with PE
and thromobcytopenia (due to myelodyplastic syndrome),
successful emergency pulmonary embolectomy has been
reported [36]. However, large-scale data in cancer patients
is lacking [15].
3.5. IVC ﬁlter. Placement of IVC ﬁlter is recommended in
patients with contraindication to anticoagulation, failure ofCardiology Research and Practice 5
Table 3: Multivariate analysis of the risk of developing fatal and major bleeding in cancer patients with venous thromboembolism (VTE)
[31, 32].
Fatal bleeding Major bleeding
Variables Odds ratio (95% CI) P-value Variables Odds ratio (95% CI) P-value
Body weight <60kg 2.5 (1.1–5.3) .021 Recent major bleeding 2.4 (1.1–5.1) .003
Recent major bleeding 3.0 (0.96–9.1) .058 CrCl < 30 ml/min 2.2 (1.5–3.4) <.001
Serum creatinine
>1.2mg/dL 2.8 (1.3–5.8) .008 Immobility for ≥4 days 1.8 (1.2–2.7) .005
Immobility for ≥4 days 4.1 (1.9–8.7) .001 Metastatic cancer 1.6 (1.1–2.3) .03
Metastatic cancer 3.1 (1.4–7.1) .006
Conﬁdence interval: CI; creatinine clearance: CrCl.
Table 4: Multivariate analysis for major bleeding and bleeding risk index classiﬁcation [34].
Risk factors Odds ratio (95%CI) P Points
Recent major bleed 2.7 (1.6–4.6) <.001 2
Serum creatinine >1.2mg/dL 2.1 (1.7–2.8) <.001 1.5
Anemia 2.1 (1.7–2.7) <.001 1.5
Cancer 1.7 (1.4–2.2) <.001 1
Clinically overt pulmonary embolism 1.7 (1.4–2.2) <.001 1
Age >75y 1.7 (1.3–2.1) <.001 1
0 point: low risk 0.1% (95% CI: 0.0–0.2) 1–4 points: intermediate risk 2.8%
(95% CI: 2.4–3.3)
>4 points: high risk7.3 % (95% CI: 4.0–9.1)
anticoagulation, massive pulmonary embolism, severe cardi-
opulmonary disease with deep vein thrombosis, and free
ﬂoating iliofemoral or inferior vena cava thrombus [11–
15, 37].
To date, there are no randomized clinical trials available
in the cancer literature to assess the long-term safety and
eﬃcacy of ﬁlters. IVC ﬁlters carry short-term and long-term
complications such as hematoma; misplacement, migration,
thrombosis, recurrent PE, ﬁlter fracture, IVC occlusion and
vena caval syndrome [38]. The insertion of an IVC ﬁlter does
not obviate the need for long-term anticoagulation [15].
3.6. Assessing and Addressing Bleeding Risks. Prior to initia-
tion of anticoagulation risk of bleeding should be assessed.
Reported bleedings (major and minor combined) in cancer
trials associated with VKA and LMWH are 3%–16% and
6%–11%, respectively [8, 23]. The Prospective registry, Reg-
istro Informatizado de La Enfermedad Thromboemb´ olic` a
(RIETE), showed that patients with VTE and evidence of
recent major bleed (<30 days prior to diagnosis of VTE)
had signiﬁcantly higher rates of fatal bleeding (4.1% versus
0.6%; P<. 001) and mortality (9.5% versus 7.7%; P<. 005)
compared to those without [39]. Multivariate analyses of
RIETE showed that patients with a body weight of less than
60 kilograms, serum creatinine of >1.2mg/dL, recent major
bleeding, immobility for >4 days, clinically overt PE, and
metastatic cancer had higher odds of developing fatal or
major bleeding (Table 3)[ 31, 32] When RIETE investigators
cross-validated the predictive model into a validated group,
after determination of point scores, the incidence of major
bleeding was 0.1% (95% CI: 0.0–0.2) in low-risk patients;
2.8% (95% CI: 2.4–3.3) in those at intermediate risk, and
6.2% (95% CI: 4.0–9.1) in high-risk patients. The incidence
of major bleeding in the three groups was statistically diﬀer-
ent(P<. 001)(Table 4)[34].Theseprospectivedatahavenot
measured the eﬀect of thrombocytopenia into the bleeding
risk scores. Advanced age, renal insuﬃciency, metastatic
cancer, anemia, immobility, recent major bleeding, and
clinically overt PE should prompt healthcare providers to
closely monitor these patients for bleeding complications
while receiving anticoagulation.
Transient thrombocytopenia due to myelosuppressive
chemotherapy needs to be taken into consideration prior to
initiation of anticoagulation as bleeding risks double from
10% at a platelet count of 20,000/mm3 to 20% when the
platelet count drops to below 10,000/mm3 in solid tumor
patients [40]. The timing and kinetics of platelet nadir is
dependentonthemodeofaction,dose,andadditionofmul-
tiple cytotoxic agents. Cytotoxic agents such as ifosfamide,
carboplatin,etoposide,mesna,doxorubicin,anddacarbazine
are associated with an early nadir. Delayed nadir can be seen
in regimens containing nitrosoureas and melphalan. Novel
agents such as lenalidomide and bortezomib can contribute
to thrombocytopenia when added to other cytotoxic agents
[40]. Enrolling cancer patients in VTE trials has been
limited due to strict inclusion criteria; mainly to prevent
bleeding complications. Cancer trials for VTE have excluded
patients with platelet count as low as 30,000/mm3 to as
high as 150,000/mm3 [16–19]. National Comprehensive
Cancer Network (NCCN) considers platelet counts of less
than 50,000/mm3 as a contraindication to prophylactic or
therapeutic anticoagulation therapy [14]. American Society
ofClinicalOncology(ASCO)recommendsusingtherapeutic6 Cardiology Research and Practice
anticoagulation in cancer patients with preexisting throm-
bocytopenia with caution; therefore, close monitoring of
platelets and hemoglobin is required in cancer patients [13].
Choosing an anticoagulant should be based upon the half-
life, reversibility, tolerability, patient’s preference, and cost
[13]. Pharmacokinetic, pharmacodynamic, and monitoring
parameters speciﬁc to each anticoagulants are discussed in
Table 2. Brieﬂy, unfractionated heparin provides a short
half-life with complete reversibility by protamine sulfate;
therefore, it is considered ideal agent for patients that may
require rapid surgical interventions such as thrombectomy.
LMWHs are considered intermediate to long-acting agents.
Partial reversal of LMWHs in bleeding can be achieved by
use of protamine sulfate. The half-life of fondaparinux is
longer than LMWHs and partial reversibility can be achieved
by administration of Recombinant factor VIIa (rVIIa) in
bleeding episodes [15, 23]. Vitamin K can be administered
for reversal of bleeding associated with VKA. Fresh frozen
plasma and cryoprecipitate can be administered in cases of
life-threateningbleedingassociatedwithanticoagulants[15].
In patients taking warfarin, Food and Drug Administration
(FDA) has made recommendations regarding the potential
beneﬁts of genotype testing, to help reduce the bleeding risks
in individual patients.
Risk of intracranial hemorrhage with thrombolytics in
PE is about 3% [3]. In a study of 104 patients with acute
PE who received ﬁbrinolytic therapy, 19% of patients expe-
rienced major bleeding. In this study, cancer, diabetes, and
an elevated INR before initiation of ﬁbrinolytic therapy were
found to be an independent predictors of major bleeding
[41].
The exact risk of bleeding in thrombocytopenic patients
with PE is unknown. Platelet count less than 150,000/mm3
has been a predictor of short-term composite event such as
mortality [42]. In clinical practice, platelet count of less than
50,000×109 is a contraindication to thrombolytic therapy
[43].
No recommendations can be made regarding the use of
thrombolytics in patients with thrombocytopenia and acute
PE, until large-scale data is available. Use of thrombolytic
agents in cancer patients requires close attention to bleeding
risks and overall prognosis.
4. Conclusion
There are several published guidelines for the treatment of
VTE in cancer patients.
However, data on the management of saddle PE and
particularly in patients with thrombocytopenia is lacking.
Large-scale prospectively collected data and future studies
are needed to address the best possible treatment option in
these patients.
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